Abstract
Resveratrol is a naturally occurring polyphenol that provides a number of anti-aging health benefits including improved metabolism, cardioprotection, and cancer prevention. Much of the work on resveratrol and cancer comes from in vitro studies looking at resveratrol actions on cancer cells and pathways. There are, however, comparatively fewer studies that have investigated resveratrol treatment and cancer outcomes in vivo, perhaps limited by its poor bioavailability when taken orally. Although research in cell culture has shown promising and positive effects of resveratrol, evidence from rodents and humans is inconsistent. This review highlights the in vivo effects of resveratrol treatment on breast, colorectal, liver, pancreatic, and prostate cancers. Resveratrol supplementation in animal models of cancer has shown positive, neutral as well as negative outcomes depending on resveratrol route of administration, dose, tumor model, species, and other factors. Within a specific cancer type, there is variability between studies with respect to strain, age, and sex of animal used, timing and method of resveratrol supplementation, and dose of resveratrol used to study cancer endpoints. Together, the data suggest that many factors need to be considered before resveratrol can be used for human cancer prevention or therapy.
Document Type
Article
Publication Date
6-1-2014
Digital Object Identifier (DOI)
http://dx.doi.org/10.1530/ERC-13-0171
Repository Citation
Carter, Lindsay G.; D'Orazio, John A.; and Pearson, Kevin J., "Resveratrol and Cancer: Focus on in vivo Evidence" (2014). Graduate Center for Nutritional Sciences Faculty Publications. 2.
https://uknowledge.uky.edu/nutrisci_facpub/2
Notes/Citation Information
Published in Endocrine-Related Cancer, v. 21, no. 3, p. R209-25.
This work is licensed under a Creative Commons Attribution 3.0 Unported License.